By M. Marin
OTCQB:AINMF
READ THE FULL AINMF RESEARCH REPORT
Company’s AI technology designed to help optimize drug development clinical trial outcomes…
NetraMark (OTCQB:AINMF) is an Artificial Intelligence (AI) company focused on developing AI and Machine Learning (ML) solutions to support the pharmaceutical industry’s ability to optimize clinical research activities. The importance of optimizing clinical activities is seen in industry statistics. Billions of dollars are spent on clinical activities to attain regulatory approval for a novel therapy, and yet the success rate of ultimately attaining regulatory approval is extremely low. Specifically, according to McKinsey, “From 2012 to 2022, inflation-adjusted [pharmaceutical] industry R&D spending increased 44 percent, from about $170 billion to $247 billion…” Market research firm Nova One Advisor forecasts that phased clinical trial spending will reach $153.59 billion by 2033, up from an estimated roughly $87 billion in 2024. This would represent a CAGR of 6.49% from 2024 to 2033. The market research firm‘s projections do not include the significant pre-clinical spending that precedes Phase 1.
Considering the cost and timeline to develop a new drug, bring it to regulatory approval, and commercialization (an average of 10-15 years at a cumulative investment of $2.6 billion[1]), PhRMA notes that less than 12% of candidates that commence Phase 1 clinical trials are ultimately approved by the FDA.
Therefore, we believe there is significant potential for technology that can help derisk and optimize clinical R&D spending. NetraMark anticipates that its insights potentially could protect millions of dollars of invested capital and is leveraging two paths to commercialization – working directly with sponsors, including pharmaceutical companies, and partnering with CROs – and in the past few months, the company has signed multiple agreements with midsized pharma companies and a clinical research organization (CRO), and has a growing sales pipeline.
Believe growing sales pipeline positions NetraMark for strong revenue advances going forward
We believe this growing sales pipeline positions NetraMark for strong revenue advances in FY 2026 going forward. Worldwide Clinical Trials is a full-service global CRO with a footprint that reaches more than 60 countries. Asklepion expects NetraMark’s AI analytics can help the pharma company demonstrate the benefits of L-citrulline in specific patient subgroups. AlgoTx is a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN). The NetraAI technology will analyze drug and placebo response variables, among other factors, to inform the design of and optimize future ATX01 trials, with the goal of accelerating development timelines and potentially lowering total costs.
- Worldwide Clinical Trials
- Asklepion Pharmaceuticals
- AlgoTherapeutix
- Biopharmaceutical company regarding a P3 trial of a novel psychiatric medicine
- Four contracts with a leading global pharmaceutical company
Last month, the company also announced partnerships with an unnamed leading biopharmaceutical company to apply the NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine and four contracts with an unnamed leading global pharmaceutical firm to support multiple late-stage clinical studies.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
________________________
[1]PhRMA (the Pharmaceutical Research and Manufacturers of America trade association)